Presented by ISoP's SxP SIG.
This presentation explores the complementary strengths of statistical and pharmacometric (PMx) approaches in clinical drug development. We will gain insight into how integrating these two quantitative disciplines – from exposure-response modeling and model-based meta-analysis to optimal designs and PK bridging studies – can yield more robust, efficient, and scientifically rigorous development programs. Through three worked examples, the presentation demonstrates that collaboration between statisticians and pharmacometricians produces outcomes neither discipline could achieve alone.